As research progresses, these molecules could lead to groundbreaking therapies, providing new hope for patients and healthcare providers alike
Clinical trials have shown statistically significant fat loss with AOD-9604 compared to placebo
Seven additional TRIUMPH Phase 3 readouts in obesity, type 2 diabetes, OSA, NASH, cardiovascular outcomes, and chronic low back pain are expected during 2026
It is one of the most powerful options currently being studied for fat loss
However, commercially available supplements claiming to deliver AOD-9604 often use oral formulations (tablets, capsules, liquids) despite their ineffective bioavailability
Snchez CA, Li H, Phelps KL, Zambrana-Torrelio C, Wang LF, Zhou P, et al